Effectiveness of REGEN-COV antibody combination in preventing severe COVID-19 outcomes

REGEN-COV, a combination of the monoclonal antibodies casirivimab and imdevimab, has been approved as a treatment for high-risk patients infected with SARS-CoV-2 within five days of their diagnosis. We performed a retrospective cohort study, and used data repositories of Israel’s largest healthcare...

Descripción completa

Detalles Bibliográficos
Autores principales: Hayek, Samah, Ben-shlomo, Yatir, Dagan, Noa, Reis, Ben Y., Barda, Noam, Kepten, Eldad, Roitman, Alina, Shapira, Shachar, Yaron, Shlomit, Balicer, Ran D., Netzer, Doron, Peretz, Alon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9344792/
https://www.ncbi.nlm.nih.gov/pubmed/35918340
http://dx.doi.org/10.1038/s41467-022-32253-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9344792/
https://www.ncbi.nlm.nih.gov/pubmed/35918340
http://dx.doi.org/10.1038/s41467-022-32253-9

Ejemplares similares